HCPCS Level II M1003: Tb Screening Prior to First-Time Biologic Therapy - OpenPayer

Summary & Overview

HCPCS Level II M1003: Tb Screening Prior to First-Time Biologic Therapy

HCPCS Level II code M1003 denotes tuberculosis screening performed and interpreted within 12 months before initiating first-time biologic or immune response modifier therapy. This pre-treatment screening is clinically important because biologic and immune-modulating agents can increase the risk of reactivation of latent Tb; documenting screening and interpretation supports safe prescribing and payer coverage determinations.

Key national payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, common billing considerations, and the clinical context for using M1003 when initiating biologic therapy. The publication highlights benchmarks for utilization, documentation expectations tied to the service, and policy considerations affecting prior authorization and pre-treatment clearance workflows.

This summary provides actionable context for revenue cycle and clinical teams: how the code fits into pre-biologic workflows, what information payers typically require for adjudication, and where to expect variation across major payers. Data not available in the input includes payer-specific reimbursement rates, associated ICD-10 diagnoses, and related codes — those details are noted as unavailable where applicable. The emphasis is national in scope, aiming to inform clinicians, billers, and policy stakeholders about the role and administrative handling of M1003 in the pre-biologic screening pathway.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareM1003HCPCS Level IItuberculosis screeningbiologic therapypre-treatment screeninginfectious diseaseoutpatient services

Billing Code Overview

HCPCS Level II code M1003 represents tuberculosis (Tb) screening performed and results interpreted within twelve months prior to initiation of first-time biologic and/or immune response modifier therapy. This service documents that a patient received appropriate Tb screening and that the findings were reviewed and interpreted before starting biologic or immune-modulating treatment.

Service type: Pre-treatment infectious disease screening and interpretation
Typical site of service: Outpatient clinic, specialty infusion or rheumatology/dermatology/immunology practice prior to initiation of biologic or immune response modifier therapy

Clinical & Coding Specifications

Clinical Context

A 52-year-old patient with moderate-to-severe rheumatoid arthritis is being evaluated in a rheumatology clinic for initiation of first-time biologic therapy (a tumor necrosis factor inhibitor). Per clinic protocol and payer requirements, the clinician documents that tuberculosis screening was performed within the prior twelve months and results were interpreted before starting the biologic. The screening may consist of a tuberculin skin test (TST) or an interferon-gamma release assay (IGRA) such as QuantiFERON; chest radiography is obtained if indicated by symptoms or test results. The workflow includes: initial visit where history and prior TB testing are reviewed; ordering or performing TST/IGRA if no record exists within 12 months; documenting results and interpretation in the medical record; placing orders for chest x-ray if test positive or if clinical concern; and recording the completed TB screening in the patient’s chart to support initiation of the biologic. Typical sites of service are outpatient specialty clinics (rheumatology, dermatology, gastroenterology) or ambulatory infusion centers coordinating biologic starts.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	When documentation supports unusual effort or complexity in TB screening interpretation or extensive counseling beyond typical evaluation.

HCPCS M1048: Oswestry Disability Index Preoperative and 3-Month Postoperative Assessment

HCPCS-M1032-ADULT-PHARMACOTHERAPY-OUD-MANAGEMENT

HCPCS M1032: Adult Pharmacotherapy for OUD

HCPCS-M1033-PHARMACOTHERAPY-INITIATION-OPIOID-USE-DISORDER

HCPCS Level II M1033: Pharmacotherapy Initiation for Opioid Use Disorder

HCPCS-M1023-ADOLESCENT-DEPRESSION-REMISSION-6-MONTHS

HCPCS M1023: Adolescent Depression Remission at Six Months

HCPCS-M1005-TB-SCREENING-NOT-PERFORMED-UNINTERPRETED-RESULTS

HCPCS Level II M1005: Tb Screening Not Performed or Results Not Interpreted

HCPCS-M1062-PATIENT-IMMUNOCOMPROMISED

HCPCS M1062: Patient Immunocompromised

HCPCS-M1009-DISCHARGE-EPISODE-OF-CARE

HCPCS M1009: Discharge/Discontinuation of Episode of Care

HCPCS-M1007-OUTPATIENT-RA-ASSESSMENT-OVER-50-PERCENT-ENCOUNTERS

HCPCS M1007: Outpatient Rheumatoid Arthritis Encounter Assessment >=50%

HCPCS-M1019-ADOLESCENT-DEPRESSION-REMISSION-12-MONTH-PHQ9

HCPCS M1019: Adolescent Depression Remission at 12 Months

HCPCS-M1061-PATIENT-PREGNANCY-ASSESSMENT-DOCUMENTATION

HCPCS Level II M1061: Patient Pregnancy

Showing 1–10 of 67

23

Taxonomy Code	Specialty	Notes
`207R00000X`	Rheumatology	Rheumatologists commonly initiate biologic therapy and document TB screening.
`207L00000X`	Dermatology	Dermatologists initiate biologics for psoriasis and record TB screening prior to therapy.
`207W00000X`	Gastroenterology	Gastroenterologists start biologics for inflammatory bowel disease and complete TB screening.
`363L00000X`	Infectious Disease	Infectious disease specialists interpret complex TB testing results and advise on treatment delays.
`261QM0800X`	Nurse Practitioner	Nurse practitioners in specialty clinics often perform ordering, testing coordination, and documentation.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`Z79.52`	Long term (current) use of systemic steroids	Patients on chronic immunosuppression may require TB screening prior to biologic initiation due to increased infection risk.
`M06.0`	Rheumatoid arthritis with rheumatoid factor	Common indication for biologic therapy; TB screening required before starting these agents.
`L40.0`	Psoriasis vulgaris	Dermatologic condition often treated with systemic biologics that require pre-treatment TB screening.
`K50.90`	Crohn's disease, unspecified, without complications	Inflammatory bowel disease frequently managed with biologics; TB screening required prior to therapy.
`D86.9`	Sarcoidosis, unspecified	Granulomatous disease in the differential of TB testing; specialty input may be required for interpretation.
`Z79.51`	Long term (current) use of nonsteroidal anti-inflammatory drugs (NSAIDs)	Indicates chronic therapy context; included as a medication background that may be documented during pre-biologic evaluation.
`Z11.1`	Encounter for screening for respiratory tuberculosis	Directly documents the intent of TB screening encounter prior to biologic initiation.
`R94.8`	Abnormal results of other specified diagnostic studies	Used to document abnormal TB test or imaging findings requiring further action before biologic start.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`86580`	Skin test; tuberculosis, intradermal (Mantoux test), per administration	Commonly performed as the TST when no IGRA available; provides documentation of recent TB screening prior to biologic start.
`86480`	Quantiferon-TB Gold test	An interferon-gamma release assay frequently used for TB screening before initiating biologics; blood draw and laboratory processing typically ordered alongside clinic visit.
`71045`	Radiologic examination, chest; single view, frontal	Single-view chest x-ray that may be obtained if TB test positive or clinical suspicion of active pulmonary disease exists before starting biologic therapy.
`71020`	Radiologic examination, chest; 2 views, frontal and lateral	Two-view chest radiograph commonly used to evaluate for active tuberculosis when indicated by screening results or symptoms.
`99000`	Handling and/or conveyance of specimen for transfer from physician's office to a lab	Often used when blood samples for IGRA are collected in clinic and transported to an external laboratory for processing.

OpenPayer